{
    "clinical_study": {
        "@rank": "141260", 
        "arm_group": {
            "arm_group_label": "Treatment (irinotecan hydrochloride)", 
            "arm_group_type": "Experimental", 
            "description": "Patients receive irinotecan hydrochloride IV over 90 minutes on days 1, 8, 15, 22, and 29. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.\nThis arm also includes laboratory biomarker analysis as an intervention."
        }, 
        "brief_summary": {
            "textblock": "This pilot clinical trial studies irinotecan hydrochloride in treating patients with breast\n      cancer and brain metastases that progressed after whole brain radiation therapy or\n      stereotactic radiosurgery. Drugs used in chemotherapy, such as irinotecan hydrochloride,\n      work in different ways to stop the growth of tumor cells, either by killing the cells or by\n      stopping them from dividing."
        }, 
        "brief_title": "A Pilot Study of Irinotecan in Patients With Breast Cancer and CNS Metastases", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Central Nervous System Metastases", 
            "Male Breast Cancer", 
            "Recurrent Breast Cancer", 
            "Stage IV Breast Cancer"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Breast Neoplasms", 
                "Neoplasm Metastasis", 
                "Neoplasms, Second Primary", 
                "Breast Neoplasms, Male"
            ]
        }, 
        "detailed_description": {
            "textblock": "PRIMARY OBJECTIVES; I. To evaluate the safety and efficacy of irinotecan (irinotecan\n      hydrochloride) in breast cancer patients with brain metastases who progressed after\n      radiation therapy.\n\n      II. To estimate central nervous system (CNS) objective response and clinical benefit rate in\n      patients with breast cancer and brain metastases treated with irinotecan.\n\n      III. To estimate progression free survival. IV. To estimate overall survival. V. To assess\n      the toxicity of Irinotecan.\n\n      OUTLINE:\n\n      Patients receive irinotecan hydrochloride intravenously (IV) over 90 minutes on days 1, 8,\n      15, 22, and 29. Courses repeat every 42 days in the absence of disease progression or\n      unacceptable toxicity.\n\n      After completion of study treatment, patients are followed up for up to 24 months."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically confirmed diagnosis of breast cancer (irrespective of receptor\n             status), with evidence of CNS disease by computed tomography (CT) or magnetic\n             resonance imaging (MRI), who have progressed after whole brain radiation therapy or\n             stereotactic radiosurgery\n\n          -  Patients must not be a candidate for surgical resection and/or further stereotactic\n             radiosurgery\n\n          -  Patients may have had an unlimited number of prior treatments, including any systemic\n             chemotherapy (excluding prior progression of disease with topoisomerase inhibitors as\n             explained below), surgical resection, whole brain radiation, stereotactic\n             radiosurgery, or radioimmunotherapy\n\n          -  Patient must have MRI of brain obtained within two weeks of study initiation for\n             staging and patients must also receive first dose within two weeks of study\n             enrollment\n\n          -  Patients must have at least one measurable brain lesion prior to start of treatment\n             (\u2265 10 mm on T1-weighted, gadolinium-enhanced MRI)\n\n          -  Karnofsky performance score greater than 60\n\n          -  At least two weeks must have elapsed since prior chemotherapy, three weeks must have\n             elapsed since last surgery, and six weeks since completion of radiation therapy\n\n          -  Hemoglobin > 9\n\n          -  Absolute neutrophil count (ANC) > 1500\n\n          -  Platelet count (plt) > 125\n\n          -  Creatinine < 1.5\n\n          -  Total bilirubin < 1.5\n\n          -  Aspartate aminotransferase and alanine aminotransferase levels within five times the\n             upper limit of normal\n\n          -  Patients may be on oral corticosteroids at stable dose (no dose change within two\n             weeks of enrollment), and may be on antiepileptic medication (except for cytochrome\n             P450 3A4 (CYP3A4) enzyme-inducing antiepileptic medications)\n\n          -  Fertile patients must use effective contraception\n\n        Exclusion Criteria:\n\n          -  Pregnancy, lactation, immunosuppression other than corticosteroids\n\n          -  Patient may be on hormonal therapy or Herceptin, but no other concurrent chemotherapy\n             is allowed\n\n          -  Patients who had progression of their breast cancer after prior administration of\n             irinotecan are excluded\n\n          -  Patients with leptomeningeal carcinomatosis as the only site of CNS involvement are\n             excluded\n\n          -  No other active malignancy except for any of the following: curatively treated basal\n             or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, other\n             malignancies considered disease-free\n\n          -  Patients using valproic acid within the last two weeks and patients with\n             contraindications to anticholinergic agents will be excluded\n\n          -  Concurrent administration of CYP3A4 enzyme-inducing antiepileptic medications (e.g.\n             phenytoin) will not be allowed (if patients are taking one of these agents, they must\n             switch to a non- enzyme-inducing antiepileptic medication prior to start of\n             treatment)\n\n          -  No history of immediate or delayed-type hypersensitivity reaction to gadolinium\n             contrast agents or other contraindication to gadolinium contrast, and no other known\n             contraindication to MRI\n\n          -  Homozygous for uridine diphosphate (UDP) glucuronosyltransferase 1 family,\n             polypeptide A1 (UGT1A1)*28 allele * All patients will be tested for UGT1A genotype\n             prior to starting treatment and be excluded if they are homozygous for the UGT1A1*28\n             allele (UGT1A1 7/7 genotype); irinotecan's active metabolite glucuronidation of\n             7-ethyl-10-hydroxycamptothecin (SN-38) is inactivated through glucuronidation by\n             uridine diphosphate glucuronosyltransferases (UGTs) mainly in the liver and is\n             excreted through the bile ducts; a meta-analysis demonstrated that the UGT1A1*28\n             genotype is moderately predictive of severe irinotecan induced hematologic toxicity\n             at moderate doses and strongly predictive at high doses, and in 2005, the Food and\n             Drug Administration (FDA) added a warning to the irinotecan packaging label that\n             patients with the UGT1A1*28 genotype were at increased risk for neutropenia"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "29", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 6, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01939483", 
            "org_study_id": "UCI 11-22", 
            "secondary_id": "2011-8497"
        }, 
        "intervention": [
            {
                "arm_group_label": "Treatment (irinotecan hydrochloride)", 
                "description": "Given IV", 
                "intervention_name": "irinotecan hydrochloride", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Campto", 
                    "Camptosar", 
                    "camptothecin-11", 
                    "CPT-11", 
                    "irinotecan", 
                    "irinotecan HCl", 
                    "U-101440E"
                ]
            }, 
            {
                "arm_group_label": "Treatment (irinotecan hydrochloride)", 
                "description": "Correlative studies", 
                "intervention_name": "laboratory biomarker analysis", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Camptothecin", 
                "Irinotecan"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Irinotecan hydrochloride", 
            "Irinotecan", 
            "CAMPTOSAR"
        ], 
        "lastchanged_date": "September 6, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Orange", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "92868"
                }, 
                "name": "Chao Family Comprehensive Cancer Center"
            }, 
            "investigator": {
                "last_name": "Rita Mehta, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Pilot Study of Irinotecan in Patients With Breast Cancer and CNS Metastases", 
        "overall_contact": {
            "email": "UCstudy@uci.edu", 
            "last_name": "Chao Family Comprehensive Cancer Center University of California, Irvine Medical Center", 
            "phone": "(877) 827-8839"
        }, 
        "overall_official": {
            "affiliation": "University of California, Irvine", 
            "last_name": "Rita Mehta, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "CNS objective response (complete response or partial response), defined as at least 20% volumetric reduction of CNS lesions in absence of increasing steroid use, progressive neurologic signs and symptoms, or progressive extra-CNS disease, based on MRI", 
                "safety_issue": "No", 
                "time_frame": "Up to 24 months"
            }, 
            {
                "measure": "Response rate of patients who have remained progression-free, based on MRI", 
                "safety_issue": "No", 
                "time_frame": "Up to 6 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01939483"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of California, Irvine", 
            "investigator_full_name": "Chao Family Comprehensive Cancer Center", 
            "investigator_title": "Cancer Center", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "The product limit estimator developed by Kaplan and Meier was used to graphically describe the distribution of survival among patients with recurrent disease.", 
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "Time between treatment initiation and death, assessed up to 24 months"
            }, 
            {
                "description": "The product limit estimator developed by Kaplan and Meier was used to graphically describe the distribution of PFS among patients with recurrent disease.", 
                "measure": "Progression free survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "Time between treatment initiation and disease progression/relapse/death, assessed up to 24 months"
            }, 
            {
                "measure": "Clinical benefit rate (objective response + stable disease at least 16 weeks)", 
                "safety_issue": "No", 
                "time_frame": "Up to 24 months"
            }, 
            {
                "description": "Tabulated by type, and worst grade experienced by the patient. Toxicity will initially be summarized within each cohort or patient subgroup, and then collectively summarized.", 
                "measure": "Frequency of toxicity occurrence, assessed by National Cancer Institute's Common Terminology Criteria (CTC) for Adverse Events version 4.0", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 24 months"
            }
        ], 
        "source": "University of California, Irvine", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of California, Irvine", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}